Crossmark

NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma

Crossref DOI link: https://doi.org/10.1007/s10238-025-01885-8

Published Online: 2026-01-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sun, Yi

Cheng, Qiang

Zhou, Qiaoxia

Xu, Yu

Wang, Guoqiang

Xu, Chunwei

Wang, Wenxian

Cai, Shangli

Chen, Wenzheng
License Information

Text and Data Mining valid from 2026-01-17

Version of Record valid from 2026-01-28
More Information

Article History

Received: 22 July 2025

Accepted: 4 September 2025

First Online: 17 January 2026

Declarations

:

: The clinical data analyzed in the present study were retrieved from public cohorts, and therefore ethics approval and consent are not necessary.

: Not applicable.

: The authors declare no competing interests, except the employment of Qiaoxia Zhou, Yu Xu, Guoqiang Wang, and Shangli Cai in Burning Rock Biotech.

Document is current

Any future updates will be listed below